MedTrace Logo

Prostate Adaptive Radiation Therapy

NCT06547398 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2026-02-05

No results posted yet for this study

Summary

Prostate ART is a two phase study looking at using adaptive radiotherapy to help reduce toxicity for prostate cancer patients.

Adaptive radiotherapy is a new technology that provides the ability to account for daily changes in anatomy. Adaptive radiotherapy also provides a foundation for which radiotherapy margins might be safely reduced.

Phase 1 of this study is looking to see if a radiation therapist centred adaptive workflow can be implemented. If phase 1 of this study is safe and feasible, the study will proceed to phase 2.

Part 2 of the study looks at using adaptive technology to reduce radiation treatment margins. The primary aim of this study is to see whether margin reduced treatment using adaptive radiotherapy can reduce side effects for prostate cancer patients.

Conditions

  • Prostatic Neoplasms

Interventions

RADIATION

Adaptive radiotherapy +/- Margin Reduction

Radiotherapy using adaptive technology to recontour and replan daily as required. Reductions in the PTV margin will also be introduced in the second phase of this study.

RADIATION

Image guided radiotherapy

Standard radiation treatment used in the department of radiation oncology for prostate cancer

Sponsors & Collaborators

  • Northern Sydney and Central Coast Area Health Service

    collaborator OTHER

  • Royal North Shore Hospital

    lead OTHER

Principal Investigators

  • Andrew Prof Kneebone, MBBS · Northern Sydney Local Health District

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-01
Primary Completion
2029-10-31
Completion
2031-10-31

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06547398 on ClinicalTrials.gov